Abstract:Background and aims Eosinophilia-associated coronary vasospasm is an under-recognized and scarcely reported life-threatening condition for whose management is undefined. Preliminary data suggest that eosinophil-targeted therapies could be beneficial. Our aim is to provide an in-depth report of the clinical picture, outcomes and predictors of relapse in patients with eosinophilia-associated coronary vasospasm. Methods European multicentric retrospective study, gathering twenty centers across France, Italy and Spain. Patients of 15 years or more with definite or suspected coronary vasospasm according to the 2017 International standardization of diagnostic criteria for vasospastic and concomitant (± 48 hours) eosinophilia (threshold: 0.5 x 109/L) were included in this study. Outcomes included vasospasm relapse and other major cardiovascular events (MACE) during follow-up. Predictors of relapse were assessed using bidirectional stepwise regression analysis. Results Thirty-seven patients (median age: 52 [42-64] years, 43% women) were included, among which 16 (43%) had aspirin-exacerbated respiratory disease, 16 (43%) and 13 (35%) fulfilled classification criteria for Eosinophilic Granulomatosis with Polyangiitis (all with negative antineutrophil cytoplasmic antibodies) and Hypereosinophilic syndrome, respectively. There was no predominant coronary territory involved. A iatrogenic trigger was evidenced in 7 (19%) patients, consisting in all cases but one of non-steroidal anti-inflammatory drugs. After a median follow-up of 32 [12-63] months, 20 (54%) patients relapsed (median time to first relapse: 10 [5−29] months), despite vasodilators regimen in 95% of cases. Besides coronary vasospasm(s), 13 (35%) patients experienced an additional MACE. In multivariate analysis, persistent eosinophilia (i.e. absolute eosinophil count > 0.5 x 109/L at the time of coronary vasospasm relapse or at last follow-up for relapsing and non-relapsing patients respectively) was the sole indepedendent predictor of relapse (Odds Ratio 8.87 [3.28-24.82]; p<0.001). All six patients treated with interleukin-5 biologics remained relapse-free under treatment. Conclusions Eosinophilia-associated coronary vasospasm can occur in patients with type 2 inflammation. Long-term normalization of absolute eosinophil counts appears crucial in preventing the recurrence of eosinophilia-associated coronary vasospasm, while conventional use of vasodilators seems ineficient.

Endomyocardial involvement in asymptomatic Latin American migrants with eosinophilia related to helminth infection: A pilot study

Eosinophilia Endomyocardial Disease:A Case Review

Case report: eosinophilic myocarditis in hypereosinophilic syndrome: a journey to heart transplantation

Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities

Characterization of Latin American migrants at risk for Trypanosoma cruzi infection in a non-endemic setting. Insights into initial evaluation of cardiac and digestive involvement

A Retrospective Longitudinal Study of Refugees with Eosinophilia at an Academic Center in the US from 2015-2020

Sublingual microcirculatory alterations in Chagas disease: an observational study in an endemic rural population

Eosinopenia in patients with acute myocardial infarction- longitudinal imaging insights from the CAPRI study

Pathophysiology of hypereosinophilia-associated heart disease

Clinical picture, outcomes and predictors of relapse in eosinophilia-associated coronary vasospasm: data from a European multicentric study

Eosinophilic Myocarditis: An Often-Overlooked Diagnosis in Patients Presenting with Heart Failure

The Diagnostic Value of Transthoracic Echocardiography for Eosinophilic Myocarditis: A Single Center Experience from China

Acute Eosinophilic Myocarditis and Hyper IgE in HIV Infection: A Case Report

Eosinophilic phenotype in adults with severe asthma in a tropical middle-income country: The ISAR Colombia experience

Multimodality imaging of eosinophilic myocarditis (loeffler's endocarditis) in a patient with idiopathic hypereosinophilic syndrome

Increased hypoxic proliferative response and gene expression in erythroid progenitor cells of Andean highlanders with chronic mountain sickness

Cardiac Mechanics and Valvular and Vascular Abnormalities in Hypereosinophilic Syndrome

Exploring novel perspectives on eosinophilic inflammation in severe asthma

Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy

An Unexpected Cause For Adult-Onset Asthma, Anosmia, And Acute Heart Failure

Eosinophilic Myocarditis: From Bench to Bedside